与利巴韦林比较宿主因子CaMK Ⅱ与PACT 对降低甲型流感病毒聚合酶活性的影响

中国药物警戒 ›› 2016, Vol. 13 ›› Issue (1): 1-4.

• 基础与临床研究 • 下一篇

与利巴韦林比较宿主因子CaMK Ⅱ与PACT 对降低甲型流感病毒聚合酶活性的影响

包蕾¹,郭姗姗²,崔晓兰²

1.首都医科大学 ,北京 100069;
2.中国中医科学院中药研究所, 北京 100029

收稿日期:2015-12-14 修回日期:2016-02-25 出版日期:2016-01-08 发布日期:2016-02-25
通讯作者: 崔晓兰,女,博士,研究员·博导,中药药理。
作者简介:包蕾, 女, 在读硕士, 中药药理。
基金资助:
国家自然科学基金(81303290); 北京市自然科学基金(7132141); 中国博士后基金(2015T80208); 中国中医科学院自主选题项目(ZZ2014041,ZXKT15017, 自由探索第二批) 。

Influence of Host Factors CaMKⅡ and PACT in Activity Reduction of Influenza A Virus RNA Polymerase Compared with Ribavirin

BAO Lei¹, GUO Shan-shan², CUI Xiao-lan²

1.Capital Medical University, Beijing 100069, China;
2. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100029, China

Received:2015-12-14 Revised:2016-02-25 Online:2016-01-08 Published:2016-02-25

摘要/Abstract

摘要： 目的对比利巴韦林 ,观察宿主因子 CaMKⅡ和 PACT对甲型流感病毒 RNA聚合酶的作用。方法采用双荧光素酶报告基因法检测 293T细胞中甲型流感病毒聚合酶的相对表达量 ,分别判断利巴韦林处理与两种蛋白的沉默对甲型流感病毒 RNA聚合酶的影响。结果沉默 CaMKⅡ蛋白后流感病毒 RNA聚合酶相对表达量降低 ,屏蔽PACT蛋白后甲型流感病毒 RNA聚合酶相对表达量降低明显 ,但利巴韦林的处理对 RNA聚合酶的抑制更为明显。结论利巴韦林能明显降低流感病毒 RNA聚合酶活性 ,宿主因子 CaMKⅡ和 PACT在流感病毒 RNA聚合酶的合成过程中起着重要的作用 ,但 PACT的作用要更明显于 CaMKⅡ。

关键词: 利巴韦林, 宿主因子PACT, CaMKⅡ, 甲型流感病毒RNA聚合酶

Abstract: Objective To observe the effect of host factors CaMK Ⅱ and PACT on influenza A virus RNA polymerase compared with ribavirin. Methods Dual luciferase reporter gene approach was used to detect relative expression of influenza A virus polymerase in 293T cells, judging the influence of influenza A virus polymerase by treatment with ribavirin and silencing protein CaMK Ⅱ and PACT. Results Silence CaMK Ⅱ and PACT all decreased the relative expression of influenza A virus RNA polymerase. But the inhibition was more obvious by dealing with ribavirin. Conclusion Ribavirin can control the expression of the influenza A virus RNA polymerase. The host factors CaMK Ⅱ.. and PACT play an important role in the process of synthesis of the influenza A virus RNA polymerase, and protein PACT is more significant than CaMK Ⅱ .

Key words: ribavirin, host factors PACT, CaMK Ⅱ , influenza A virus RNA polymerase

中图分类号:

R978.7

包蕾,郭姗姗,崔晓兰. 与利巴韦林比较宿主因子CaMK Ⅱ与PACT 对降低甲型流感病毒聚合酶活性的影响[J]. 中国药物警戒, 2016, 13(1): 1-4.

BAO Lei, GUO Shan-shan, CUI Xiao-lan. Influence of Host Factors CaMKⅡ and PACT in Activity Reduction of Influenza A Virus RNA Polymerase Compared with Ribavirin [J]. Chinese Journal of Pharmacovigilance, 2016, 13(1): 1-4.

参考文献

[1] Ishihama A. A multi-functional enzyme with RNA polymerase and RNase activities: molecular anatomy of influenza virus RNA polymerase[J]. Biochimie, 1996, 78(11-12): 1097-1102.
[2] Konig R, Stertz S, Zhou Y, et al. Human Host Factors Required for Influenza Virus Replication[J]. Nature, 2010,463(7282):813-817.
[3]郭姗姗 ,时宇静 ,高英杰 .半枝莲总黄酮抗副流感病毒的作用机制 [J].药学学报 ,2009,44(12):1348-1352.
[4] Bouvier N M, Palese P. The biology of influenza virus[J].Vaccine, 2008,26(S4):D49-53.
[5] Rebmann T, Zelicoff A. Vaccination against influenza: role and limitations in pandemic intervention plans[J]. Expert Review of Vaccines, 2012,11(8):1009-1019.
[6] DeClercq E. Antiviral agents active against influenza A viruses. Nature Reviews[J]. Drug Discovery, 2006,5(12):1015-1025.
[7] Pinto L H, Lamb R A. Controlling influenza virus replication by inhibiting its proton channel[J]. Molecular BioSystems, 2007,3(1):18-23.
[8] Bright R A, Medina M J, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2)viruses isolated worldwide from 1994 to 2005: a cause for concern[J]. Lancet, 2005,366(9492): 1175-1181.
[9] Vattem K M, Staschke K A, Wek R C. Mechanism of activation of the double-stranded-RNA-dependent protein kinase, PKR: role of dimerization and cellular localization in the stimulation of PKR phosphorylation of eukaryotic initiation factor-2(eIF2)[J]. Europ J Biochem, 2001, 268(13):3674-3684.
[10] Blais J D, Filipenko V, Bi M, et al. Activating transcrip tionfactor 4 is translationally regulated by hypoxic stress[J]. Mon Cell Biolm, 2004, 24(17):7469-7482.
[11] Stojdl D F, Abraham N, Knowles S, et al. The murine doublestranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus[J]. J Virol, 2000,74(20):9580-9585.
[12] Soderling T R. CaM-kinases modulators of synaptic plasticity[J]. Cyrr Opin Neurobiol, 2000, 10(3): 375-380.
[13] Li W, Sun W, Liu L, et al. IL-32: A Host Proinflammatory Factor against Influenza Viral Replication Is Upregulated by Aberrant
Epigenetic Modifications during Influenza A Virus Infection[J]. The Journal of Immunology,2015,195(11):5056-5065
[14] Ludwig S, Ehrhardt C, Neumeier E R, et al. Influenza VirusAP-1-dependent Gene Expression Requires Activation of the JNK Signaling Pathway[J]. The Journal of Biological Chemistry, 2001, 276(24): 10990-10998.

与利巴韦林比较宿主因子CaMK Ⅱ与PACT 对降低甲型流感病毒聚合酶活性的影响

Influence of Host Factors CaMKⅡ and PACT in Activity Reduction of Influenza A Virus RNA Polymerase Compared with Ribavirin

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics

[1]	张敬升, 高双荣, 庞博, 包蕾, 孙静, 陈梦苹, 徐英莉, 曹姗, 郭姗姗, 赵荣华, 崔晓兰. 金振口服液对流感病毒H1N1/FM1株和副流感病毒感染致小鼠肺炎的药理作用[J]. 中国药物警戒, 2023, 20(1): 46-51.
[2]	李美云, 唐广良, 陈志宏, 何鑫, 陈沈珏, 李昕, 刘丽华. 107例利巴韦林不良反应分析[J]. 中国药物警戒, 2022, 19(7): 770-774.
[3]	杨淼, 杨莉, 赵志刚. 利巴韦林在我国7个城市儿科应用现状与合理应用评价[J]. 中国药物警戒, 2022, 19(4): 408-412.
[4]	周瑞欧, 季欢欢, 龚莉, 张妮, 宋林. 基于FAERS数据库对利巴韦林、洛匹那韦/利托那韦、磷酸氯喹不良事件检测与评价[J]. 中国药物警戒, 2022, 19(2): 205-209.
[5]	张晋, 刘子昀, 张军, 杨建军, 张晓钰, 姜凤丽, 乌伊萍, 杨蓓蓓, 李兴欢, 陈玉艳, 刘冬, 任炜. 利巴韦林治疗新型冠状病毒肺炎的有效性及安全性的Meta分析[J]. 中国药物警戒, 2020, 17(7): 393-398.
[6]	李清芳, 刘欢, 张丹丹, 杨悦, 张惠霞, 夏旭东, 刘超. 利巴韦林儿童应用风险分析与建议[J]. 中国药物警戒, 2018, 15(2): 83-89.
[7]	李海龙, 赵厚宇, 林鸿波, 刘翠丽, 沈鹏, 詹思延. 鄞州区门诊利巴韦林注射剂18至44岁育龄使用者用药情况分析[J]. 中国药物警戒, 2018, 15(2): 78-82.
[8]	林鸿波, 刘翠丽, 沈鹏, 李海龙, 赵厚宇, 詹思延. 基于鄞州区域医疗数据的利巴韦林临床使用的分析[J]. 中国药物警戒, 2018, 15(2): 73-77.
[9]	郭姗姗,包蕾,崔晓兰. 黄芩苷对宿主因子PACT干扰后流感病毒RNA聚合酶活性的影响[J]. 中国药物警戒, 2016, 13(3): 129-131.
[10]	胡志强. 蓝芩口服液联合利巴韦林气雾剂治疗疱疹性咽峡炎疗效观察[J]. 中国药物警戒, 2011, 8(12): 711-712.